683 Capital Management, LLC Cyma Bay Therapeutics, Inc. Transaction History

683 Capital Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$5.88 - $9.59 $4.12 Million - $6.71 Million	-700,000 Reduced 58.33%	500,000 $4.36 Million
Q4 2022 Feb 14, 2023	SELL	$3.22 - $6.27 $869,400 - $1.69 Million	-270,000 Reduced 18.37%	1,200,000 $7.52 Million
Q2 2022 Aug 15, 2022	BUY	$1.72 - $3.39 $636,400 - $1.25 Million	370,000 Added 33.64%	1,470,000 $4.34 Million
Q4 2021 Feb 14, 2022	BUY	$3.23 - $4.6 $3.55 Million - $5.06 Million	1,100,000 New	1,100,000 $3.72 Million

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of 683 Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on 683 Capital Management, LLC with notifications on news.